ProMIS Neurosciences Enters Material Definitive Agreement

TL;DR

ProMIS Neurosciences just signed a big deal, filing an 8-K on 7/21/25.

AI Summary

On July 21, 2025, ProMIS Neurosciences Inc. entered into a material definitive agreement. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is incorporated in Ontario, Canada, and its principal executive offices are located at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2.

Why It Matters

This filing indicates a significant new contract or partnership for ProMIS Neurosciences, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry significant risks related to the terms, obligations, and potential outcomes of the agreement.

Key Numbers

• 001-41429 — SEC File Number (Identifies the company's filing with the SEC.)
• 98-0647155 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• AMORFIX LIFE SCIENCES LTD (company) — Former company name
• July 21, 2025 (date) — Date of earliest event reported
• Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S 3E2 (location) — Principal executive offices address

FAQ

From the Filing

0001558370-25-009352.txt : 20250722 0001558370-25-009352.hdr.sgml : 20250722 20250722063021 ACCESSION NUMBER: 0001558370-25-009352 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250721 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 251138626 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 pmn-20250721x8k.htm 8-K PROMIS NEUROSCIENCES INC._July 21, 2025 0001374339 false 0001374339 2025-07-21 2025-07-21 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) ​ Ontario, Canada      001-41429      98-0647155 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) ​ ​ Suite 200 , 1920 Yonge Street , Toronto , Ontario             M4S 3E2 (Address of principal executive offices)       (Zip Code) ​ Registrant’s telephone number, including area code: ( 416 ) 847-6898 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class      Trading Symbol(s)      Name of Each Exchange on Which Registered Common Shares, no par value per share ​ PMN The Nasdaq Capital Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company   ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ Item 1.01 Termination of a Material Definitive Agreement. As previously disclosed, on January 5, 2024, ProMIS Neurosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with BTIG, LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, its